An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
作者： Kevan C. Herold , Brian N. Bundy , S. Alice Long , Jeffrey A. Bluestone , Linda A. DiMeglio
关键词:
摘要: … Despite improvements in care, the desired glycemic targets are not achieved in most patients with type 1 diabetes, 2 and an increased risk of complications and death persists. Two …
elsevier.com
sci-hub.se 参考文章(43)
David L. DeMets, Gordon Lan, The alpha spending function approach to interim data analyses Cancer treatment and research. ,vol. 75, pp. 1- 27 ,(1995) , 10.1007/978-1-4615-2009-2_1
JS Skyler, D Brown, HP Chase, E Collier, C Cowie, GS Eisenbarth, J Fradkin, G Grave, C Greenbaum, RA Jackson, FR Kaufman, JP Krischer, JB Marks, JP Palmer, A Ricker, DA Schatz, D Wilson, WE Winter, J Wolfsdorf, A Zeidler, H Dickler, RC Eastman, NK Maclaren, JI Malone, PR Robertson, D Cuthbertson, LM Rafkin-Mervis, K Herold, L Rafkin-Mervis, B Aneju, D Conboy, R Cook, MA Dennis, L Finney, S Harris, D Matheson, M McCulloch-Olsen, T Smith, J Valenzuela, N Vega, OB Crofford, D DeMets, JM Lachin, A Rossini, A Schiffrin, M Steffes, A Tsiatis, B Zinman, Effects of insulin in relatives of patients with type 1 diabetes mellitus The New England Journal of Medicine. ,vol. 346, pp. 1685- 1691 ,(2002) , 10.1056/NEJMOA012350
Terry M. Therneau, Patricia M. Grambsch, Modeling Survival Data: Extending the Cox Model ,(2000)
Diane K Wherrett, Jane L Chiang, Alan M Delamater, Linda A DiMeglio, Stephen E Gitelman, Peter A Gottlieb, Kevan C Herold, Daniel J Lovell, Trevor J Orchard, Christopher M Ryan, Desmond A Schatz, David S Wendler, Carla J Greenbaum, Type 1 Diabetes TrialNet Study Group, None, Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report Diabetes Care. ,vol. 38, pp. 1975- 1985 ,(2015) , 10.2337/DC15-1429
James E. Tooley, Nalini Vudattu, Jinmyung Choi, Chris Cotsapas, Lesley Devine, Khadir Raddassi, Mario R. Ehlers, James G. McNamara, Kristina M. Harris, Sai Kanaparthi, Deborah Phippard, Kevan C. Herold, Changes in T‐cell subsets identify responders to FcR‐nonbinding anti‐CD3 mAb (teplizumab) in patients with type 1 diabetes European Journal of Immunology. ,vol. 46, pp. 230- 241 ,(2016) , 10.1002/EJI.201545708
Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson, Jane L. Chiang, Dana Dabelea, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jeffrey P. Krischer, Åke Lernmark, Robert E. Ratner, Marian J. Rewers, Desmond A. Schatz, Jay S. Skyler, Jay M. Sosenko, Anette-G. Ziegler, Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. ,vol. 38, pp. 1964- 1974 ,(2015) , 10.2337/DC15-1419
Shona J Livingstone, Daniel Levin, Helen C Looker, Robert S Lindsay, Sarah H Wild, Nicola Joss, Graham Leese, Peter Leslie, Rory J McCrimmon, Wendy Metcalfe, John A McKnight, Andrew D Morris, Donald WM Pearson, John R Petrie, Sam Philip, Naveed A Sattar, Jamie P Traynor, Helen M Colhoun, Scottish Diabetes Research Network epidemiology group, Scottish Renal Registry, Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010 JAMA. ,vol. 313, pp. 37- 44 ,(2015) , 10.1001/JAMA.2014.16425
David A. Schoenfeld, Sample-size formula for the proportional-hazards regression model. Biometrics. ,vol. 39, pp. 499- 503 ,(1983) , 10.2307/2531021
Kevan C. Herold, Sahar Usmani-Brown, Tara Ghazi, Jasmin Lebastchi, Craig A. Beam, Melena D. Bellin, Michel Ledizet, Jay M. Sosenko, Jeffrey P. Krischer, Jerry P. Palmer, β Cell death and dysfunction during type 1 diabetes development in at-risk individuals Journal of Clinical Investigation. ,vol. 125, pp. 1163- 1173 ,(2015) , 10.1172/JCI78142
Kevan C. Herold, Dario A. A. Vignali, Anne Cooke, Jeffrey A. Bluestone, Type 1 diabetes: translating mechanistic observations into effective clinical outcomes Nature Reviews Immunology. ,vol. 13, pp. 243- 256 ,(2013) , 10.1038/NRI3422